JAG2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P04984(JAG2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04984(JAG2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The JAG2 antibody targets the Jagged2 (JAG2) protein, a key ligand in the Notch signaling pathway, which plays critical roles in cell-cell communication, differentiation, and tissue development. JAG2. a transmembrane protein belonging to the DSL (Delta/Serrate/LAG-2) family, binds to Notch receptors to activate downstream signaling. This pathway regulates diverse cellular processes, including stem cell maintenance, apoptosis, and immune responses. Dysregulation of JAG2-Notch signaling is implicated in cancers, developmental disorders, and immune diseases.

JAG2 antibodies are widely used in research to study protein expression, localization, and function. They enable detection of JAG2 in techniques like immunohistochemistry, flow cytometry, and Western blotting. In cancer biology, JAG2 overexpression has been observed in tumors such as breast, ovarian, and pancreatic cancers, correlating with poor prognosis and metastasis. Therapeutic JAG2-blocking antibodies are under exploration to inhibit oncogenic Notch activation.

Structurally, JAG2 contains extracellular EGF-like repeats, a DSL domain for receptor binding, and a cysteine-rich region. Antibodies may target specific domains to modulate signaling. Challenges include ensuring specificity due to homology with JAG1 and managing off-target effects. Current research also focuses on JAG2's role in immune regulation, particularly in T-cell development and autoimmune conditions. Both monoclonal and polyclonal JAG2 antibodies are available, each with distinct applications in basic and translational studies.